➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Dow
Merck
Harvard Business School
McKesson

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Patent: 9,352,037

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,352,037
Title:Compositions and methods to enhance the immune system
Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host\'s immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host\'s immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
Inventor(s): van den Berg; Timo Kars (Amsterdam, NL)
Assignee: STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL)
Application Number:14/153,714
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,352,037
Patent Claims:see list of patent claims

Details for Patent 9,352,037

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL) 2028-04-23 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL) 2028-04-23 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL) 2028-04-23 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL) 2028-04-23 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL) 2028-04-23 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL) 2028-04-23 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL) 2028-04-23 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,352,037

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Johnson and Johnson
Mallinckrodt
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.